• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher

    12/26/23 2:43:36 PM ET
    $AZN
    $GRCL
    $ID
    $IINN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday.

    The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17.

    Check This Out: Top 3 Tech And Telecom Stocks That Could Blast Off In December

     

    Leading and Lagging Sectors

    Energy shares jumped by 1.3% on Tuesday.

    In trading on Tuesday, health care shares fell by 0.01%.

     

    Top Headline

    The FHFA house price index rose by 0.3% from the prior month in October.

     

    Equities Trading UP

    Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares shot up 60% to $9.91. AstraZeneca Plc (NASDAQ:AZN) agreed to acquire Gracell Biotechnologies, further strengthening AstraZeneca's cell therapy portfolio.

    Shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) got a boost, surging 36% to $1.63 after the company announced 95% accuracy results for HYLA Blood Sensor. Additionally, the company plans FDA submission for clearance in 2024.

    RayzeBio, Inc. (NASDAQ:RYZB) shares were also up, gaining 101% to $61.38 after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion.

     

    Equities Trading DOWN

    Adit Know Labs, Inc. (NYSE:KNW) shares dropped 20% to $0.4677 after the company announced an $18 million mixed shelf offering.

    Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) were down 32% to $1.96 after the company announced that it received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.

    PARTS iD, Inc. (NYSE:ID) was down, falling 43% to $0.0489 after the company entered into a Credit Agreement with Fifth Star.

    Also Check This Out: Beat Inflation With These 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts

     

    Commodities

    In commodity news, oil traded up 3.3% to $75.98 while gold traded up 0.1% at $2,069.40.

    Silver traded down 0.4% to $24.465 on Tuesday while copper rose 0.1% to $3.9050.

     

    Asia Pacific Markets

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 gaining 0.16%, and China’s Shanghai Composite Index falling 0.68%. India’s S&P BSE Sensex, meanwhile, rose 0.32%.

    India's current account deficit shrank to $8.3 billion in the July-September quarter from $30.9 billion in the year-ago quarter. Japan’s unemployment rate came in unchanged at 2.5% in November.

     

    Economics

    The Chicago Fed National Activity Index increased to +0.03 in November, versus a revised reading of -0.66 in the prior month.

    The S&P CoreLogic Case-Shiller 20-city home price index rose by 4.9% year-over-year in October, recording the largest surge since Nov. 2022.

    The FHFA house price index rose by 0.3% from the prior month in October.

    Now Read This: How To Earn $500 A Month From Nike Stock Following Quarterly Report

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $GRCL
    $ID
    $IINN

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    Milestone Pharmaceuticals Inc.
    $MIST
    12/15/2025$8.00Hold → Buy
    TD Cowen
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    Milestone Pharmaceuticals Inc.
    $MIST
    9/11/2025$4.00Overweight
    Wells Fargo
    Milestone Pharmaceuticals Inc.
    $MIST
    6/5/2025$5.00Buy
    H.C. Wainwright
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    More analyst ratings

    $AZN
    $GRCL
    $ID
    $IINN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on AstraZeneca

    Citigroup initiated coverage of AstraZeneca with a rating of Buy

    1/27/26 8:43:14 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Medical Officer Bharucha David

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:19 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Oliveto Joseph

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:21 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chief Commercial Officer Muller Lorenz

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:13 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

    US ACT on Health Equity contributions support AstraZeneca's long-term ambition in health equity and total more than $18 million to date AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity. During its fifth year, AstraZeneca's ACT on Health Equity initiative will fund 47 nonprofit programs whose missions support the goal of advancing health equity and focus on healthcare access, nutrition, lung health, and eliminating b

    2/11/26 9:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca results: FY and Q4 2025

    Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

    2/10/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/10/26 11:55:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/9/26 6:42:15 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Inspira Technologies Oxy B.H.N. Ltd.

    6-K - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Filer)

    2/6/26 9:20:54 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    Financials

    Live finance-specific insights

    View All

    AstraZeneca results: FY and Q4 2025

    Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period AstraZeneca: Revenue and EPS summary   FY 2025 % Change Q4 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 55,573 9 9 14,538 9 7 - Alliance Revenue 3,067 39 38 959 34 33 Product Revenue2 58,640 10 10 15,497 10 8 Collaboration Revenue 99 (89) (89) 6 (99) (99) Total Revenue 58,739 9 8 15,503 4

    2/10/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

    RA'ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ:IINN) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company's core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent equity investment (the "Equity Investment"), positioning

    1/8/26 8:50:00 AM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

    First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc.  (NASDAQ:MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conver

    12/12/25 8:00:00 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inspira Technologies Oxy B.H.N. Ltd.

    SC 13G/A - Inspira Technologies OXY B.H.N. Ltd (0001837493) (Subject)

    11/14/24 4:08:42 PM ET
    $IINN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

    SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    10/29/24 4:30:20 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

    SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    7/16/24 6:06:24 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $GRCL
    $ID
    $IINN
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Vistagen Appoints Nick Tressler as Chief Financial Officer

    Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective today, December 1, 2025. "I am excited to welcome Nick to Vistagen as our CFO. His financial and strategic acumen and extensive operational experience in the biopharmaceutical industry will be instrumental as we accelerate into our next phase," said President and Chief Executive Officer of Vistagen, Shawn Singh. "I look forward to his contributions to our leadership team and the po

    12/1/25 8:30:00 AM ET
    $AZN
    $SENS
    $VTGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments